Treatment Patterns in Patients With Eosinophilic Oesophagitis Referred for Expert Consultation

BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) patients deemed treatment-refractory are frequently referred to tertiary centres. We aimed to characterize expert perspectives on patients referred for refractory EoE, including its causes, prevalence, and evaluation. METHODS: We conducted an anonymous and blinded cross-sectional survey of international EoE experts (n = 52) assessing provider characteristics, referral patterns, perceived causes of treatment failure, diagnostic approaches, and prior therapies. Descriptive statistics and subgroup analyses were performed. RESULTS: Respondents were predominantly gastroenterologists (77%) and practiced in academic settings (87%) with high EoE volume. Experts estimated that true refractoriness to medical and diet therapy was 15% [IQR 10-25], median 31% [20-50], respectively. Patients referred for perceived refractory EoE had been treated with PPIs (80%), topical steroids (55%), and elimination diets (45%); dupilumab (10%) was infrequently trialled. Half of the patients referred had been on combination therapy. After referral, experts focused on assessing medication adherence (98%), dosing (92%), and administration technique (90%), with most repeating endoscopy (85%) and performing oesophageal dilation (42%). The causes of perceived refractory disease were subtherapeutic dosing (34%), incorrect medication administration (30.5%), inappropriate medication choice (26.5%), and dietary non-adherence (26%). Functional and behavioural contributors including co-existing oesophageal hypersensitivity (20%), ARFID (9%), and rumination syndrome (5%) were also reported. Experience in treating EoE patients assessed by less than or greater than 10 years did not affect most results. CONCLUSIONS: Among international experts, most referred EoE patients labelled as refractory had received suboptimal medical and dilation therapy. This highlights opportunities to optimize care along guideline recommendations prior to referral.

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-08-27
DOI
https://doi.org/10.1111/apt.70951
Primary Topic
Eosinophilic Esophagitis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment Patterns in Patients With Eosinophilic Oesophagitis Referred for Expert Consultation

Sydney Pomenti, Alexa Choy, David A. Katzka, Nirmala Prabu Gonsalves et al.
Alimentary Pharmacology & Therapeutics
Eosinophilic Esophagitis
article

Treatment Patterns in Patients With Eosinophilic Oesophagitis Referred for Expert Consultation

Sydney Pomenti, Alexa Choy, David A. Katzka, Nirmala Prabu Gonsalves, Emma Fanuele, Elina Stoffel, Evan S. Dellon
article en

Abstract

BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) patients deemed treatment-refractory are frequently referred to tertiary centres. We aimed to characterize expert perspectives on patients referred for refractory EoE, including its causes, prevalence, and evaluation. METHODS: We conducted an anonymous and blinded cross-sectional survey of international EoE experts (n = 52) assessing provider characteristics, referral patterns, perceived causes of treatment failure, diagnostic approaches, and prior therapies. Descriptive statistics and subgroup analyses were performed. RESULTS: Respondents were predominantly gastroenterologists (77%) and practiced in academic settings (87%) with high EoE volume. Experts estimated that true refractoriness to medical and diet therapy was 15% [IQR 10-25], median 31% [20-50], respectively. Patients referred for perceived refractory EoE had been treated with PPIs (80%), topical steroids (55%), and elimination diets (45%); dupilumab (10%) was infrequently trialled. Half of the patients referred had been on combination therapy. After referral, experts focused on assessing medication adherence (98%), dosing (92%), and administration technique (90%), with most repeating endoscopy (85%) and performing oesophageal dilation (42%). The causes of perceived refractory disease were subtherapeutic dosing (34%), incorrect medication administration (30.5%), inappropriate medication choice (26.5%), and dietary non-adherence (26%). Functional and behavioural contributors including co-existing oesophageal hypersensitivity (20%), ARFID (9%), and rumination syndrome (5%) were also reported. Experience in treating EoE patients assessed by less than or greater than 10 years did not affect most results. CONCLUSIONS: Among international experts, most referred EoE patients labelled as refractory had received suboptimal medical and dilation therapy. This highlights opportunities to optimize care along guideline recommendations prior to referral.

Alimentary Pharmacology & Therapeutics
Northwestern University (US), University of North Carolina at Chapel Hill (US), Medical University of South Carolina (US), Columbia University (US)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Celgene, Regeneron Pharmaceuticals, Celldex Therapeutics, BioCryst, Dr. Falk Pharma
Openalex Percentile: Top 8%
Eosinophilic Esophagitis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.